🔴 Anixa Biosciences is trading 11.86% down in pre-market; cause remains unclear

Anixa Biosciences is trading 11.86% lower at $2.60, with the cause of the October 5 pre-market decline unclear.

• Shares are down from the October 2 close of $2.95.
• Search results showed no fresh company-specific announcement; the latest news was an October 1 update that a second patient was treated in the fifth cohort of its ovarian cancer CAR-T trial.
• Major U.S. indexes were near flat, offering no clear explanation; no volume or trading-activity data was provided.